Возможности и перспективы применения колхицина в комплексной терапии у пациентов с COVID-19
https://doi.org/10.30629/0023-2149-2021-99-3-165-171
Аннотация
Об авторах
П. А. Лебедев
ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России
Россия
Россия
Самара
А. А. Гаранин
ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России
Россия
Россия
Андрей Александрович Гаранин - канд. мед. наук, ассистент кафедры пропедевтической терапии
Самара
Е. В. Паранина
ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России
Россия
Россия
443095, Самара
А. В. Чернышев
ГБУЗ «Самарская областная клиническая больница им. В.Д. Середавина»
Россия
Россия
443095, Самара
П. А. Дулин
ФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова» (Московский филиал) Минобороны России
Россия
Россия
107392, Москва
Список литературы
1. Dalbeth N., Lauterio T.J., Wolfe H.R. Mechanism of Action of Colchicine in the Treatment of Gout. Clin. Ther. 2014;36(10):1465–79. DOI: https://doi.org/10.1016/j.clinthera.2014.07.017
2. Nidorf S.M., Eikelboom J.W., Budgeon C.A. et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J. Am. Coll. Cardiol. 2013;61(4):404–410. DOI: http://doi.org/10.1016/j.jacc.2012.10.027
3. Tardif J.C., Kouz S., Waters D.D. et al. Effi cacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N. Engl. J. Med. 2019;381(26):2497–2505. DOI: http://doi.org/10.1056/NEJMoa1912388
4. Katsanos A.H., Palaiodimou L., Price C. et al. Colchicine for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis. Eur. J. Neurol. 2020;27(6):1035–1038. DOI: http://doi.org/10.1111/ene.14198
5. Shah B., Pillinger M., Zhong H., Cronstein B. Eff ects of acute colchicine administration prior to percutaneous coronary intervention: COLCHICINE-PCI Randomized Trial. Circ. Cardiovasc. Inter. 2020;13(4):e008717. DOI: http://doi.org/10.1161/CIRCINTERVENTIONS.119.008717
6. Stewart S., Yang K. C., Atkins K. et al. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials Arthritis Res. Therapy. 2020;22(1):28. DOI: https://doi.org/10.1186/s13075-020-2120-7
7. Nishiga M., Wang D. W., Han Y. et al. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat. Rev. Cardiol. 2020;17(9):543–558. DOI: http://doi.org/10.1038/s41569-020-0413-9
8. Richardson S., Hirsch J.S., Narasimhan M. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–2059. DOI: https://doi.org/10.1001/jama.2020.6775
9. Grasselli G., Zangrillo A., Zanella A. et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323(16):1574–1581. DOI: https://doi.org/10.1001/jama.2020.53942020
10. Zhou F., Ting Y., Ronghui D. et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62. Published Online March 9, 2020. https://doi.org/10.1016/S0140-6736(20)30566-3
11. Schaller T., Hirschbühl K., Burkhardt K. et al. Postmortem examination of patients with COVID-19. JAMA. 2020;323(24):2518–2520. DOI: https://doi.org/10.1001/jama.2020.8907
12. Shang J., Du L., Han N. et al. Severe acute respiratory syndrome coronavirus 2 for physicians: Molecular characteristics and host immunity (Review). Mol. Med. Rep. 2021;23(4):1. DOI: https://doi.org/10.3892/mmr.2021.11901.
13. Мареев В.Ю., Орлова Я.А., Павликова Е.П. и др. Упреждающая противовоспалительная и антикоагулянтная терапия в лечении продвинутых стадий новой коронавирусной инфекции (COVID-19). Разбор клинических случаев и дизайн иссле дования: колхицин против руксолитиниба и секукинумаба в от крытом проспективном рандомизируемом исследовании у пациентов с COVID-19 (КОЛОРИТ). Кардиология. 2020;60(9): 4–21.
14. Thakur V., Ratho R.K., Kumar P. et al. Multi-Organ Involvement in COVID-19: Beyond Pulmonary Manifestations. J. Clin. Med. 2021;10(3):446. DOI: DOI: https://doi.org/10.3390/jcm10030446
15. Bellosta R., Luzzani L., Natalini G. et al. Acute limb ischemia in patients with COVID-19 pneumonia. J. Vasc. Surg. 2020;72(6):1864–1872. DOI: https://doi.org/10.1016/j.jvs.2020.04.483
16. Deng Q., Hu B., Zhang Y. et al. Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China. Int. J. Cardiol. 2020;311:116–121. DOI: https://doi.org/10.1016/j.ijcard.2020.03.087
17. Martos L., Oto J., Fernández-Pardo Á. et al. Increase of Neutrophil Activation Markers in Venous Thrombosis-Contribution of Circulating Activated Protein C. Int. J. Mol. Sci. 2020;21(16):5651. DOI: https://doi.org/10.3390/ijms21165651
18. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции COVID-19. Версия 10 (08.02.2021 г.) утвержденная МЗ РФ.
19. Chen I.Y., Moriyama M., Chang M.F., Ichinohe T. Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Infl ammasome. Front. Microbiol. 2019;10:50. DOI: https://doi.org/10.3389/fmicb.2019.00050
20. Rodrigues T.S., de Sá K.S.G., Ishimoto A.Y. et al. Infl ammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J. Exp. Med. 2021;218(3):e20201707. DOI: https://doi.org/10.1084/jem.20201707
21. Dupuis J., Sirois M.G., Rhéaume E. et al. Colchicine reduces lung injury in experimental acute respiratory distress syndrome. PLoS ONE. 2020;15(12):e0242318. DOI: https://doi.org/10.1371/journal.pone.0242318
22. Papadopoulos C., Patoulias D., Teperikidis E. et al. Colchicine as a potential therapeutic agent against cardiovascular complications of COVID-19: an exploratory review. SN Compr. Clin. Med. 2020;4:1–11. DOI: https://doi.org/10.1007/s42399-020-00421-x
23. Tardif J.-C., Bouabdallaoui N., L’Allier P. et al. Effi cacy of Colchicine in Non-Hospitalized Patients with COVID-19. MedRxiv preprint this version posted January 27, 2021. DOI: https://doi.org/10.1101/2021.01.26.21250494
24. Salah H.M., Mehta J.L. Meta-analysis of the Eff ect of Colchicine on Mortality and Mechanical Ventilation in COVID-19. Am. J. Cardiol. 2021;145:170–172. DOI: https://doi.org/10.1016/j.amjcard.2021.02.005
25. Deftereos S.G., Giannopoulos G., Vrachatis D.A. et al. Eff ect of Colchicine vs Standard Care on Cardiac and Infl ammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. JAMA Netw. Open. 2020;3(6):e2013136. DOI: https://doi.org/10.1001/jamanetworkopen.2020.13136
26. The ECLA PHRI COLCOVID Trial. Eff ects of Colchicine on Moderate/ High-risk Hospitalized COVID-19 Patients. (COLCOVID). https://clinicaltrials.gov/ct2/show/NCT04328480
27. Kaul S., Gupta M., Bandyopadhyay D. et al. Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes. Am. J. Cardiovasc. Drugs. 2020:1–14. DOI: https://doi.org/10.1007/s40256-020-00459-1
Рецензия
Для цитирования:
Лебедев П.А., Гаранин А.А., Паранина Е.В., Чернышев А.В., Дулин П.А. Возможности и перспективы применения колхицина в комплексной терапии у пациентов с COVID-19. Клиническая медицина. 2021;99(3):165-171. https://doi.org/10.30629/0023-2149-2021-99-3-165-171
For citation:
Lebedev P.A., Garanin A.A., Paranina E.V., Chernyshev A.V., Dulin P.A. Possi bilities and perspectives of colchicine application in complex therapy in patients with COVID-19. Clinical Medicine (Russian Journal). 2021;99(3):165-171. (In Russ.) https://doi.org/10.30629/0023-2149-2021-99-3-165-171
Просмотров: 3801
Послать статью по эл. почте 